The first patient, a 74-year-old man, witnessed significant tumor reduction within a day of CARv3-TEAM-E T-Cell infusion. However, subsequent scans revealed cancer progression months later despite initial improvement. Similarly, a 57-year-old woman experienced near-complete regression of her tumor five days post-therapy, yet the cancer resurged within a month.